Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.
New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?
Related Items
Video Library published on September 6, 2018 in Video
Video Library published on September 6, 2018 in Video
Video Library published on September 6, 2018 in Video
Video Library published on September 6, 2018 in Video
Video Library published on September 6, 2018 in Video
Video Library published on September 6, 2018 in Video
Video Library published on September 6, 2018 in Video
Last modified: July 25, 2018